New hope for Tough-to-Treat lung cancer: trial targets genetic weakness
NCT ID NCT06219174
Summary
This study is testing whether adding an older drug called DFMO to the immunotherapy pembrolizumab can help control advanced lung cancer in people whose tumors have a specific genetic change (STK11 mutation). The first part finds the safest dose, and the second part checks if the combination effectively shrinks tumors. It is for adults with advanced lung cancer who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.